We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




PCR Test Detects Co-Infection by Novel Species of Parasite in Severe Cases of Visceral Leishmaniasis

By LabMedica International staff writers
Posted on 03 Nov 2023
Print article
Image: The protozoan Leishmania infantum can affect the spleen, liver, lymph nodes and bone marrow (Photo courtesy of Wikimedia Commons)
Image: The protozoan Leishmania infantum can affect the spleen, liver, lymph nodes and bone marrow (Photo courtesy of Wikimedia Commons)

Leishmaniasis remains an overlooked health concern worldwide, with Brazil experiencing an increase in the number of individuals co-infected by the protozoans Leishmania infantum and Crithidia. The most serious form of the disease, visceral leishmaniasis (VL), targets vital organs such as the spleen and liver, and if not correctly identified and treated, can be fatal. L. infantum is the primary cause of VL, and health professionals in VL-prevalent regions of Brazil are observing a spike in cases of co-infection by both L. infantum and Crithidia, the latter traditionally seen as a non-human-infecting mosquito parasite. Current diagnostic methods fall short of providing a clear picture due to the absence of simple, specific tests. Now, a new test can accurately identify the causative agent in less than two hours, enabling targeted treatment.

Researchers from the Federal University of São Carlos (UFSCar, São Carlos, Brazil) have developed a PCR test that analyzes the genetic material from samples and generates results quickly, in under two hours, thereby enhancing the detection process for the pathogens causing severe VL. This new approach represents a significant improvement over existing diagnostic tests that only recognize antibodies rather than the actual pathogens. The dye-based quantitative PCR assay, developed by the researchers, targets specific sequences from both L. infantum and Crithidia, which are found in experimental and clinical samples. Previously, two separate tests were necessary—one for each pathogen—but now, any laboratory equipped to conduct qPCR tests (which have become more common due to the COVID-19 pandemic) can perform this test. The test can also be a valuable tool for epidemiological studies, monitoring parasite levels, and checking the effectiveness of treatments.

In their research, the new test demonstrated high accuracy in detecting and quantifying both L. infantum and Crithidia in various samples, including those from humans and animals like dogs, cats, and even insects, whether through skin biopsies or bone marrow aspirations. The study analyzed 62 parasites from the tissues of VL patients, with 51 indicating the presence of Crithidia. Furthermore, the dual infection of Crithidia and L. infantum was discovered in two recent VL cases in Brazil. The researchers emphasize not only the test's accuracy but also suggest that Crithidia infection may be more common than previously understood and that co-infections with both parasites are particularly associated with the most severe cases of the disease.

“Although there are other molecular methods for identifying species, they require DNA sequencing of the sample, which is laborious, slow and expensive. Our test analyzes the parasite’s genetic material directly from vectors and human or animal tissue,” said Sandra Regina Costa Maruyama, a professor of evolutionary genetics and molecular biology at UFSCar. “Identifying the species of parasite correctly ensures that appropriate measures can be taken quickly to prevent progression of the patient’s clinical condition, potentially reducing mortality. It also points to the possible development of more specific drugs and treatments in the future.”

Related Links:
UFSCar 

Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Malondialdehyde HPLC Test
Malondialdehyde in Serum/Plasma – HPLC
New
Chlamydia Trachomatis Assay
Chlamydia Trachomatis IgG

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.